Jose Alvarez
Pulmonary Disease · Plantation, FLNPI 1346203304
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AstraZeneca at 32.6% of the total.
Across 321 payments — averaging $26.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$476
- Regeneron Healthcare Solutions, Inc.$320
- Boston Scientific$292
- Sanofi$287
- plus $3K from 29 others
Across 1 payment — averaging $41,460 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$41K
What the payments were for
- Food & beverage$8,12897%
- Education$2403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 98 | $2,732 |
| GSK | 86 | $1,672 |
| Boehringer Ingelheim | 20 | $476 |
| Regeneron Healthcare Solutions, Inc. | 9 | $320 |
| Boston Scientific | 11 | $292 |
| Sanofi | 12 | $287 |
| Grifols USA, LLC | 16 | $257 |
| Actelion Pharmaceuticals US, Inc. | 4 | $256 |
| Mylan Specialty L.p. | 7 | $230 |
| Inari Medical, Inc. | 1 | $193 |
| Inspire Medical Systems, Inc. | 2 | $171 |
| Harmony Biosciences LLC | 8 | $162 |
| Mallinckrodt Hospital Products Inc. | 3 | $160 |
| Insmed, Inc. | 2 | $158 |
| Mallinckrodt Enterprises LLC | 1 | $125 |
| Pulmonx Corporation | 1 | $97 |
| Verona Pharma, Inc. | 3 | $77 |
| Paratek Pharmaceuticals, Inc. | 4 | $70 |
| Viatris Specialty LLC | 3 | $70 |
| United Therapeutics Corporation | 2 | $65 |
| Sunovion Pharmaceuticals Inc. | 6 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Jazz Pharmaceuticals Inc. | 4 | $59 |
| Lilly USA, LLC | 2 | $57 |
| Inogen, Inc. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Circassia Inc. | 2 | $30 |
| Merck | 1 | $27 |
| Pfizer | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Resmed Corp | 1 | $20 |
| Optinose US, Inc. | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$694
- FLOWTRIEVER CATHETER, S$387
- NUCALA$237
- BREZTRI$236
- Inspire$141
- ACTHAR$125
- Yupelri$124
- BEVESPI AEROSPHERE$122
- FARXIGA$122
- DUPIXENT$114
How this compares
$8,367 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 54 | $730,511 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 479 | $383,720 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 354 | $261,405 |
| TezspireTezepelumab-Ekko | 38 | $158,249 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 261 | $142,441 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 174 | $87,027 |
| Breo ElliptaFluticasone/Vilanterol | 74 | $39,479 |
| SymbicortBudesonide/Formoterol Fumarate | 138 | $38,342 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 778 | $19,500 |
| Spiriva HandihalerTiotropium Bromide | 26 | $15,098 |
| BreynaBudesonide/Formoterol Fumarate | 58 | $12,576 |
| Spiriva RespimatTiotropium Bromide | 13 | $10,725 |
| Ventolin HfaAlbuterol Sulfate | 155 | $10,567 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $10,128 |
| DuleraMometasone/Formoterol | 22 | $8,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $476 | $828,263241 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,672 | $573,749826 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $2,732 | $463,939541 claims |
| MerckDulera | $27 | $8,56422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Plantation
- Frank HullPlantation$90K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.